<SEC-DOCUMENT>0001140361-22-022458.txt : 20220609
<SEC-HEADER>0001140361-22-022458.hdr.sgml : 20220609
<ACCEPTANCE-DATETIME>20220609161251
ACCESSION NUMBER:		0001140361-22-022458
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220609
FILED AS OF DATE:		20220609
DATE AS OF CHANGE:		20220609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		221006102

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10038594_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.3.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;">
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;"></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">&#160;REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the Month of June 2022</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39992</div>
      <div>&#160;</div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;">
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: center; font-weight: bold;">(Translation of registrant&#8217;s name into English)</div>
      <div>&#160;</div>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;">
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">92 Park Drive</div>
      <div style="text-align: center; font-weight: bold;">Milton Park</div>
      <div style="text-align: center; font-weight: bold;">Abingdon, Oxfordshire OX14 4RY</div>
      <div style="text-align: center; font-weight: bold;">United Kingdom</div>
      <div style="text-align: center; font-weight: bold;">&#160;(Address of principal executive office)</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000;"> </div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div style="font-family: 'Times New Roman', Times, serif;">&#9746;<font style="font-family: 'Times New Roman';">&#160; Form 20-F&#160; &#160; &#9744;&#160; Form 40-F</font></div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160; &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160; &#9744;</div>
      <div>&#160;</div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div>
        <div>&#160;</div>
        <div style="color: rgb(0, 0, 0); font-weight: bold;">Appointment of New Director</div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify;">On June 9, 2022, Immunocore Holdings plc (the &#8220;Company&#8221;) announced the appointment of Siddharth (Sid) Kaul as a non-executive member of its board of directors, effective June 8, 2022. Mr. Kaul will serve as a Class
        II director and also serve as a member of the Audit Committee and as a member of the Remuneration Committee, effective June 8, 2022.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Mr. Kaul retired as Group Treasurer and Head of Business Planning and Analysis at Novartis International AG in 2021 after a 17-year career at the company, where his previous roles included serving as Novartis&#8217; Chief
        Financial Officer, Pharma Europe and Chief Financial Officer, U.S. Prior to joining Novartis, Mr. Kaul spent two decades at The Procter &amp; Gamble Company, where he worked in a number of finance leadership roles across financial planning and
        analysis, strategic planning, and accounting and auditing in the United States and Japan. Mr. Kaul holds a B.S. degree in business administration from West Virginia University and an M.B.A from Indiana University Bloomington.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">Press Release</div>
      <div>&#160;</div>
      <div style="text-align: justify;">On June 9, 2022, the Company issued a press release regarding the appointment of Siddharth Kaul as a non-executive member of its board of directors, effective June 8, 2022. A copy of this press release is furnished
        as Exhibit 99.1 to this Report on Form 6-K.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">Incorporation by Reference</div>
      <div>&#160;</div>
      <div style="text-align: justify;">This Report on Form 6-K, including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the Company&#8217;s registration statement on Form F-3ASR (File No. 333-264105) and the Company&#8217;s registration
        statements on Form S-8 (File Nos. 333-226457 and 333-265000) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z833182219f1148768e5a113bf26705cd" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 9%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; font-weight: bold;">No.</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 9%; vertical-align: middle;">&#160;</td>
            <td style="width: 1%; vertical-align: middle;">&#160;</td>
            <td style="width: 90%; vertical-align: bottom;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 9%; vertical-align: top;">
              <div><a href="brhc10038594_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 90%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release dated June 9, 2022.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z61c0e63f2fc841a281b50d6bcd8a09b6" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div style="font-weight: bold;">IMMUNOCORE HOLDINGS <font style="color: rgb(0, 0, 0);">PLC</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: bottom;">&#160;</td>
            <td style="vertical-align: bottom;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Date: June 9, 2022</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div>/s/ <font style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Bahija Jallal, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10038594_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.3.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div id="DSPFPageHeader" style="width: 100%;"></div>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 99.1</font><br>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

        <tr>
          <td style="border-bottom: 2px solid #F79646; width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="border-bottom: 2px solid #F79646; width: 50%; text-align: right;">
            <div><img src="image00001.jpg">
              <div><br>
              </div>
            </div>
          </td>
        </tr>

    </table>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: center; font-weight: bold; font-size: 12pt;">Immunocore Appoints Siddharth Kaul to its Board of Directors</div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: justify;">(OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US, 9 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;), a commercial-stage biotechnology company pioneering the
      development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces the appointment of Siddharth (Sid) Kaul as a
      non-Executive member of its Board of Directors, effective June 8, 2022. Sid will serve as a Class II director and also serve as a member of the Audit and Remuneration committees.</div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: justify;">Sid is a seasoned finance professional with deep expertise within the life sciences industry. He retired as Group Treasurer and Head of Business Planning and Analysis at Novartis in 2021 after a 17-year career at the
      company, where his previous roles included serving as Novartis&#8217; Chief Financial Officer, Pharma Europe and Chief Financial Officer, Pharma U.S. Sid led the Novartis strategic review and spin-off of Alcon, Novartis&#8217; eye care business.</div>
    <div style="text-align: left;"> <br>
    </div>
    <div style="text-align: justify;">Prior to joining Novartis, Sid spent two decades at Procter &amp; Gamble, where he worked in a number of finance leadership roles across financial planning and analysis, strategic planning, and accounting and auditing
      in the United States and Japan. Sid holds a Bachelor of Science in Business Administration from West Virginia University and a Master of Business Administration from Indiana University Bloomington.</div>
    <div style="text-align: left;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman'; font-weight: bold;">Sir John Bell, Chairman of the Immunocore Board of Directors, said: </font><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;Sid&#8217;s wealth of experience will be invaluable to the Immunocore Board as we continue to focus on the commercial roll-out of our lead product KIMMTRAK&#174; for the treatment of patients with metastatic uveal melanoma
        and advance our clinical pipeline in oncology and infectious diseases.&#8221;</font></div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman'; font-style: italic;"> <br>
      </font></div>
    <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman'; font-weight: bold;">Sid Kaul, Non-Executive Director of Immunocore, said: </font><font style="font-family: 'Times New Roman'; font-style: italic;">&#8220;Immunocore is truly at the forefront of innovation in the field of TCR therapeutics and has made tremendous progress with recent regulatory approvals of its lead product, KIMMTRAK, and the acceleration of its clinical
        development pipeline. I look forward to working closely with the Board and Senior Management Team as we continue to build upon this momentum.&#8221;</font></div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: center;">##</div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: left; font-weight: bold;">About Immunocore</div>
    <div>
      <div style="text-align: justify;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing monoclonal TCRs Against X disease &#8211; designed to
        treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five
        clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. <br>
      </div>
      <div style="text-align: left;"> <br>
      </div>
      <div style="text-align: left;"> <br>
      </div>
      <div style="text-align: left;"> <br>
      </div>
      <div style="text-align: left;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 1px; color: #000000; text-align: center;">
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageFooter" style="width: 100%;">
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">Immunocore Holdings plc, 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK</div>
        <font style="font-weight: normal; color: rgb(0, 0, 0); font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;"> </font>
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">T: +44 (0)1235 438600&#160; |&#160; www.immunocore.com</div>
        <font style="font-weight: normal; color: rgb(0, 0, 0); font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;"> </font>
        <div style="font-weight: normal; color: rgb(0, 0, 0); font-size: 8pt; font-style: normal; font-variant: normal; text-transform: none;">Registered in England no: 6456207&#160; |&#160; VAT No. GB 939 6694 55</div>
        <div style="text-align: left;"> <br>
        </div>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%Page % of 3%-->
    <div>
      <div style="text-align: left; font-weight: bold;">Forward Looking Statements</div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman';">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private
          Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the
          Company&#8217;s business plan and strategy, the marketing and therapeutic potential of KIMMTRAK, and the advancement of the Company&#8217;s pipeline. Any forward-looking statements are based on management&#8217;s current expectations of future events and are
          subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company&#8217;s control. These risks
          and uncertainties include, but are not limited to, the impact of the ongoing COVID-19 pandemic and the Omicron variant on the Company&#8217;s business, strategy, clinical trials and financial position; Immunocore&#8217;s ability to maintain regulatory
          approval of KIMMTRAK&#160;including the timing or likelihood of expansion into additional markets or geographies; its ability to execute its commercialization strategy for KIMMTRAK; its ability to develop, manufacture and commercialize its other
          product candidates; commercial supply of KIMMTRAK or any future approved products, and launching, marketing and selling of KIMMTRAK or any future approved products; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial
          infrastructure and to successfully launch, market and sell KIMMTRAK; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore&#8217;s ability to obtain, maintain
          and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates
          that are lower than expected; changes in expected or existing competition; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it is developing; and the success of
          Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and
          Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 3, 2022, as well as discussions of potential risks, uncertainties,
          and other important factors in the Company&#8217;s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information,
          except as required by law.</font></div>
    </div>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter"></div>
      <div style="text-align: left;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 2 of 3</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div id="DSPFPageHeader" style="width: 100%;"></div>
    </div>
    <div style="text-align: left; font-weight: bold;">
      <div>
        <div style="font-weight: bold;">CONTACT:</div>
        <div>&#160;</div>
      </div>
      <div style="font-weight: bold;">Immunocore</div>
      <div style="font-weight: normal;">Debra Nielsen, Head of Communications</div>
      <font style="font-weight: normal;"> </font>
      <div style="font-weight: normal;">T: +1 (610) 368-8602</div>
      <font style="font-weight: normal;"> </font>
      <div style="font-weight: normal;">E: debra.nielsen@immunocore.com</div>
      <font style="font-weight: normal;"> </font>
      <div style="font-weight: normal;">Follow on Twitter: @Immunocore</div>
      <div> <br>
      </div>
      Consilium Strategic Communications (corporate and financial)</div>
    <div style="text-align: left;">Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson</div>
    <div style="text-align: left;">T: +44 (0)203 709 5700</div>
    <div style="text-align: left;">E: <u>Immunocore@consilium-comms.com</u></div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: left; font-weight: bold;">Investor Relations</div>
    <div style="text-align: left;">Clayton Robertson, Head of Investor Relations</div>
    <div style="text-align: left;">T: +1 (215) 384-4781</div>
    <div style="text-align: left;">E: ir@immunocore.com</div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: left;"><br>
    </div>
    <div style="text-align: left;"></div>
    <div style="text-align: left;"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">Page 3 of 3</font></div>
    <div style="text-align: left;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <div id="DSPFPageFooter" style="width: 100%;"><br>
    <div> <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  > /@# 2(  A$! Q$!_\0
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MQV'\Z]4\$Z%;>'/"^G:99HJI#"NXJ/ON1EF/U-'*J:YI*[O8.=U)<L796O\
M>>?7GB?XF^'(C>:YX=TS4M/3F7^SW82H.YQD\#Z5Z+X3U^T\3Z!:ZM8+*EO<
M*2%E0JP(."/_ *];%</\8=5?P]\--7GL<0RF(01;!C9O(7C'3@FINJC44K,J
MSI)R;NC%UCXDZCJ>MW&C?#S1UUBYMSMGO9FVVT3>F1C=^8_&JUSX@^*>AQF\
MU3P]I.I6:?-)%8NPE4>W)S^1KJ_A+H5MH/@#1X+5 &GMTN9GQR[NH8D_GC\*
M["FYQB[*.A,83DN:4K,YOP+XPTSQGI'V[2F960[)X)!B2%_1A_6N1\6>-?%<
M/Q$D\,>%=,TR\=+-;O-T[(<$X/.X#TK*,47A3]HB"*P_=6FOV9>:%1A?-&[G
M\US^)J::^M;#]I"YFOKF"VB_L55WS2!%SN'&35J$5*Z5U:Y#J2<4F[.]F7GU
MOXL0*9)?"^AS(O)2*Z.YOI\U;OP]\?0^*YKS3[NQFTO7+'_CYLICD@?WE/<9
MK;F\6>'88V>77=+5%&23=I_C7FG@B=?%OQJU7Q/HRR#1+:T%I]IVE5N9, <9
MZ_X >M*RE%MQM8IMPE%1E>YK^-?&OB>R^($'AGPMINFWDTMI]I'VIV0]3GG(
M':F?VM\6_P#H7/#O_@4?_BJP?&NOZ?X:^/\ 8:CK$S0VBZ44+A"_)+8X'-=7
M_P +G\$?]!.7_P !9/\ XFJY6DN6%]"%-.4N:=M3;\$W?B^Z:[_X3#3=.L@H
M7[/]CE+[^N[/)QVHK3\,>(M-\3Z6-0T:9IK4NT8<H4Y'7@\T5SRWU5CJA:VC
MN>>?$3_DM'@#Z2T[X]_Z[P-_V'[>NVUKPE8ZMXGTC7;F6X6[TO=Y*HP"-GKN
M&,_K2^+O"=CXI;23?RW$?]FWB7L7E,!N=>@;(/%:QJ).+[&,J4FI+N_\B3QM
MX:L_%OAR[TG4!A)5S'(!DQ./NN/H?ZBF>!?"]IX0\-VNE60!\L;I9<8,LA^\
MQ_STQ7045ES/EY>AMR1YN:VIY+\"_P#D->//^PL?_9J/"_\ R</XO_Z\8/\
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M<\+@#CFNAQ3E5_><T11I?N^21X3\)/$47BOXR:[K$,3P^?I40>)NJ.OEJP_
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'-XMVU5C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
